zhuang liu - Pharma

Author Information

Zhuang Liu is affiliated with the Institute of Functional Nano & Soft Materials (FUNSOM) at the Jiangsu Key Laboratory for Carbon-based Functional Materials and Devices, Soochow University, located in Suzhou, Jiangsu, China. This institution is renowned for its research in advanced materials and nanotechnology, focusing on innovative solutions in the fields of medicine and engineering.

Research Contributions

In 2022, Zhuang Liu made significant contributions to the field of cancer therapy and drug delivery systems. His work includes developing DNA-based materials to enhance radiotherapy and stimulate immune responses, utilizing lipid-coated nanoparticles for pH-responsive drug delivery, and engineering artificial antigen-presenting cells for personalized cancer immunotherapy. Additionally, he explored albumin-based therapeutics for synergistic cancer treatment, and designed immunogenic nanomedicine for chemo-sonodynamic therapy. Liu's research extends to innovative strategies for bone repair and novel approaches in cancer immunotherapy and chemotherapy.

Aliases

No aliases are provided for Zhuang Liu in the given information.

Publication and Citation Metrics

Metric	Value
Total Citations	62,822
h-index	121
Total Publications	320

Publications:

DNA-Based MXFs to Enhance Radiotherapy and Stimulate Robust Antitumor Immune Responses.

DOI: 10.1021/acs.nanolett.1c04888

Year: 2022

Lipid-Coated CaCO3 Nanoparticles as a Versatile pH-Responsive Drug Delivery Platform to Enable Combined Chemotherapy of Breast Cancer.

DOI: 10.1021/acsabm.1c01234

Year: 2022

DNA Engineered Lymphocyte-Based Homologous Targeting Artificial Antigen-Presenting Cells for Personalized Cancer Immunotherapy.

DOI: 10.1021/jacs.1c09316

Year: 2022

Albumin-Based Therapeutics Capable of Glutathione Consumption and Hydrogen Peroxide Generation for Synergetic Chemodynamic and Chemotherapy of Cancer.

DOI: 10.1021/acsnano.1c08536

Year: 2022

Immunogenic nanomedicine based on GSH-responsive nanoscale covalent organic polymers for chemo-sonodynamic therapy.

DOI: 10.1016/j.biomaterials.2022.121428

Year: 2022

Targeting Endogenous Hydrogen Peroxide at Bone Defects Promotes Bone Repair (Adv. Funct. Mater. 10/2022)

DOI: 10.1002/adfm.202270063

Year: 2022

Percutaneous implantation of ethanol fueled catalytic hydrogel suppresses tumor growth by triggering ferroptosis

DOI: 10.1016/j.mattod.2022.03.013

Year: 2022

Epigenetic Platinum Complexes Breaking the "Eat Me/Don't Eat Me" Balance for Enhanced Cancer Chemoimmunotherapy.

DOI: 10.1021/acs.bioconjchem.1c00576

Year: 2022

Nanovaccines with cell-derived components for cancer immunotherapy.

DOI: 10.1016/j.addr.2021.114107

Year: 2022

Collagen-targeted tumor-specific transepithelial penetration enhancer mediated intravesical chemoimmunotherapy for non-muscle-invasive bladder cancer.

DOI: 10.1016/j.biomaterials.2022.121422

Year: 2022

What Are the Challenges of Clinical Trials?

What is Medication Management?

What are Contract Research Organizations (CROs)?

What Causes Adverse Drug Events?

What are the Regulatory Requirements for Generic Drugs?

What Types of Medications are Used?

How Does the Patent System Affect Generic Competition?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

Why Are Clinical Trials Important?

Who Can Participate in Clinical Trials?

Partnered Content Networks

Relevant Topics